Huerta VD, Hernández ANJ, Parra RJA, Vargas AG

Language: Spanish
References: 12
Page: 313-318
PDF size: 78.82 Kb.

ABSTRACT

Introduction. Diabetes mellitus type 2 is a major cause of chronic kidney disease in our country. A national prevalence of type 2 diabetes mellitus 7%, and of these about 40% have chronic kidney disease. Anemia is a consequence of chronic kidney disease erythropoietin deficiency, finding a predominantly normochromic normocytic anemia from stage 3 renal function. Another cause of anemia in our country is iron deficiency finding a prevalence greater than 30% in adults 50%. Many studies have shown that anemia increases cardiovascular risk and treatment in patients with chronic kidney disease with erythropoietin to achieve Hb levels between 11 to 12 g/dL, however, before this treatment is recommended to treatment with iron patients with serum ferritin below 100 pg/mL, so we designed this study.
Objective. Quantify ferritin levels in patients diagnosed with type 2 diabetes mellitus and chronic kidney disease in each of the stages of renal function and whether there are deficiencies. Hypothesis. Ferritin levels in patients with anemia secondary to chronic kidney disease and diabetes are altered according to stage of renal function. Study design: Transversal analytic.
Material and methods. We determined a sample of 50 patients with diabetes and chronic kidney disease patients by analyzing 10 at each stage of renal function according to KDOQI. Once accepted to participate in the study samples were taken for measurement of Hb, Hct, MCV, MCH, glucose, urea, Cr and ferritin. Weight and height was performed in all patients and estimated glomerular filtration rate with Cocroft-Gault formula. Statistical analysis. Descriptive statistics were used percentages and averages, the variables were analyzed with chi square test according to the type of variables. Test was performed and correlation coefficient of determination with a statistical significance of 0.05.
Results. Of the patients 27 were women and 23 men, average age of 55.18 years. In stage 1, the average Hb was 14.6 g/dL in stage 2, the average Hb was 11.3 g/dL, stage 3 the average Hb was 11.11 g/dL, the average stage 4 Hb was10.29 g/dL in stage 5, 8.26 g/dL, p 0.05. The correlation coefficient with significance level of 0.01. Ferritin levels were found in an average of 155 with a minimum of 6 and a maximum de1 563, 30 (60%) patients with ferritin deficiency with values below 100 pg/mL with a significant correlation of 0.01.
Conclusions. We conclude that in patients with type 2 diabetes mellitus and chronic kidney disease is decreased ferritin levels which may contribute to the degree of anemia.

REFERENCES

1. American Diabetes Association: diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(1):S13-67.

2. Alpízar SM. Guía para el manejo integral del paciente diabético. 2ª ed. México: Alfil, 2007:83.

3. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136.

4. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes Care 2000;49:1399-1408.

5. American Diabetes Association: Nephropathy in Diabetes. Diabetes Care 2004;27:S79-S83.

6. De La Cruz JJ, Cases A, De la Figuera M, et al. Prevalencia de insuficiencia renal en centros de Atención Primaria en España; Estudio EROCAP. Nefrología 2007;27(3):300-312.

7. ENSANUT México 2006.

8. Toto RD. Heart disease in diabetic patients. Semin Nephrol 2005;25:372–378.

9. New JP, Aung T, Baker PG, Yongsheng G, Pylypczuk R, Houghton J, et al. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study. Diabet Med 2008;25:564–569.

10. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, the CREATE Investigators. Normalization of Hb level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084.

11. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of Hb maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799–811.

12. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148–156.